Structure Therapeutics (GPCR) Competitors $18.19 +0.06 (+0.33%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$18.55 +0.36 (+1.95%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. MTSR, ADMA, KRYS, AKRO, RNA, PTCT, ACLX, MRUS, ZLAB, and SRRKShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Metsera (MTSR), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), Arcellx (ACLX), Merus (MRUS), Zai Lab (ZLAB), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Its Competitors Metsera ADMA Biologics Krystal Biotech Akero Therapeutics Avidity Biosciences PTC Therapeutics Arcellx Merus Zai Lab Scholar Rock Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations. Does the media refer more to GPCR or MTSR? In the previous week, Metsera had 6 more articles in the media than Structure Therapeutics. MarketBeat recorded 7 mentions for Metsera and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.79 beat Metsera's score of 0.64 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Metsera 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend GPCR or MTSR? Structure Therapeutics presently has a consensus price target of $76.17, suggesting a potential upside of 318.73%. Metsera has a consensus price target of $55.00, suggesting a potential upside of 39.42%. Given Structure Therapeutics' higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, GPCR or MTSR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$0.87-20.91MetseraN/AN/A-$209.13MN/AN/A Is GPCR or MTSR more profitable? Metsera's return on equity of 0.00% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.35% -15.71% Metsera N/A N/A N/A Do insiders & institutionals have more ownership in GPCR or MTSR? 91.8% of Structure Therapeutics shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryStructure Therapeutics beats Metsera on 6 of the 9 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04B$2.92B$5.48B$9.44BDividend YieldN/A2.49%4.01%4.02%P/E Ratio-20.9120.5328.3319.90Price / SalesN/A271.82411.9985.31Price / CashN/A41.6635.9658.29Price / Book1.207.808.345.67Net Income-$122.53M-$55.10M$3.24B$258.18M7 Day Performance-7.19%4.62%3.14%2.81%1 Month Performance-17.69%17.99%10.99%13.53%1 Year Performance-49.39%2.21%34.25%17.68% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics3.1541 of 5 stars$18.19+0.3%$76.17+318.7%-50.3%$1.04BN/A-20.91136Positive NewsMTSRMetseraN/A$42.47+8.1%$55.00+29.5%N/A$4.46BN/A0.0081Gap DownADMAADMA Biologics3.8968 of 5 stars$18.68+0.9%$27.67+48.1%+24.0%$4.46B$426.45M21.98530Positive NewsKRYSKrystal Biotech4.8343 of 5 stars$150.41+1.5%$213.75+42.1%-26.6%$4.35B$290.52M36.16210Analyst ForecastAKROAkero Therapeutics3.7851 of 5 stars$52.73+2.2%$82.50+56.5%+89.3%$4.20BN/A-27.0430News CoveragePositive NewsRNAAvidity Biosciences2.5188 of 5 stars$33.57+6.7%$66.35+97.7%-27.6%$4.05B$8.93M-11.19190Positive NewsHigh Trading VolumePTCTPTC Therapeutics4.3685 of 5 stars$49.46+1.9%$65.00+31.4%+40.4%$3.92B$806.78M7.601,410ACLXArcellx2.5579 of 5 stars$69.92+1.4%$111.23+59.1%+8.4%$3.85B$76.81M-23.3880News CoveragePositive NewsMRUSMerus2.1174 of 5 stars$55.62+2.1%$84.64+52.2%+13.4%$3.85B$36.13M-13.6337Upcoming EarningsAnalyst DowngradeZLABZai Lab3.3553 of 5 stars$34.28+4.7%$54.28+58.3%+87.8%$3.81B$398.99M-13.771,869Positive NewsGap UpSRRKScholar Rock3.2871 of 5 stars$38.59+3.1%$42.67+10.6%+333.6%$3.66B$33.19M-15.25140Analyst Revision Related Companies and Tools Related Companies Metsera Alternatives ADMA Biologics Alternatives Krystal Biotech Alternatives Akero Therapeutics Alternatives Avidity Biosciences Alternatives PTC Therapeutics Alternatives Arcellx Alternatives Merus Alternatives Zai Lab Alternatives Scholar Rock Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
